Urine and the laboratory diagnosis of 
*Chlamydia trachomatis* in males

T-W Kok, L E Payne, S E Bailey, R G Waddell

Abstract

Objective—To determine whether the use of urine samples from male patients can replace urethral swabs for the rapid detection of *Chlamydia trachomatis* by the Pharmacia EIA.

Setting—The STD clinic, Adelaide, South Australia.

Patients—There were two separate groups of male patients. Group A (398) patients provided urethral specimens for the EIA and culture tests. The patients in Group B (356) provided an urethral swab and a urine sample for the EIA test.

Methods—The urine samples and urethral swabs were tested for the presence of *C trachomatis* by the Pharmacia Chlamydia EIA. In addition, the urethral swabs from Group A patients were cultured for the organism by standard cell cultures. The infected cell cultures were identified by an immunofluorescence test using a FITC-moniclonal antibody to *C trachomatis* (Kallestad).

Results—When the EIA was validated against culture, it showed a sensitivity of 100% and a specificity of 95% with the urethral swabs from Group A patients. The urine specimens were positive in 24% of those patients who yielded a positive EIA result in the urethral swabs.

Conclusions—Although the EIA test on urethral swabs showed high sensitivity and specificity when validated against culture, our results showed that the use of urine samples cannot replace urethral swabs for the laboratory diagnosis of this sexually transmitted disease.

In order to assess the efficiency of using urine samples as a possible replacement for urethral swab to diagnose this infection in male patients, we tested urine and corresponding urethral samples from 356 male patients. The corresponding urine and urethral specimens were tested simultaneously in the same rapid enzyme immunoassay with a confirmatory blocking antibody test. This was done to establish a comparative performance of the assay with the two sampling methods. The EIA was first validated with a different group of male urethral specimens. Our results showed that the use of urine samples cannot replace urethral swabs for the laboratory diagnosis of this STD.

Methods

Patients

Patients were those attending the Central STD Clinic in Adelaide, South Australia. This clinic is the only STD clinic in the state and each year diagnoses about 50% of male genital chlamydia infections notified to the State Health Commission. There were two separate groups of male patients in this study. The patients in Group A attended the clinic between 1 June 1990 and 30 November 1990 and were selected on their likelihood of having a chlamydial infection according to one or more of the following criteria: [1] contact with an STD, [2] symptoms consistent with an STD, [3] > 4 polymorphs per high power field on urethral smear. Group A consisted of 398 patients (average age 29-4 years) who provided urethral specimens for EIA and culture. No urine samples were obtained from the patients in Group A.

Patients in Group B consisted of 356 males (average age 29-2 years) who presented to the clinic between 1 September 1991 and 4 November 1991 who were examined and screened for STD. They represented 59% of all male patients seen during the period.

A standardised sexual history was collected from all patients and the time of last voiding (LPU) to the nearest ½ hour was documented. LPU information was not available in 25-6% of patients included in Group B.

Urethral specimens

In Group A three urethral specimens were collected from each patient. The first swab was cultured for gonorrhoea and used to make a Gram-stained smear which was examined for the presence of polymorphs. The second and third swabs were used for chlamydia
test in the EIA and cell culture respectively.

**Urine specimens**

Each patient in Group B provided a urine sample after collection of two urethral swabs (for Gram stained smear, gonococcal culture and Chlamydia ELA). The median interval before collection of the urine sample and previous micturition was 21/2 hour (range 0.5–5 h). On receipt in the laboratory, 20 ml of the urine sample was spun at 2500 g/30 min at room temperature. The supernate was discarded and the pellet was resuspended in 0.5 ml of the EIA diluent buffer (Pharmacia).

**Enzyme immunoassay**

The Pharmacia Chlamydia Confirmatory EIA was used according to the manufacturer’s instructions. Each screen positive specimen was tested in the confirmatory EIA provided by the manufacturer.

**Chlamydia culture**

The cell culture method used was essentially that described by Kuo et al. Once collected, the urethral specimens were immediately placed into a cryotube of chlamydia transport medium and frozen in liquid nitrogen for transport to the laboratory. Within one hour of receipt, the specimens were inoculated onto DEAE-dextran treated Buffalo Green Monkey (BGM) epithelial cells in 96-well microtitre plates (Nunc, Denmark). The plate was centrifuged at 1 000 g (1 h/RT) and the medium was replaced before incubation at 37°C for 48 hours. After washing with PBS and fixation with methanol, the inoculated cell monolayers were stained with FITC-C. trachomatis monoclonal antibody (Kallestad) for 30 min/37°C. The wells were then washed with PBS/20 min and 90% glycerol in Tris (pH 8–6) added to each well. The microtitre wells were then examined for specific staining using an immunofluorescence inverted microscope. The presence of one or more infected cells (showing intense cytoplasmic inclusion bodies) per well was considered *C. trachomatis* culture positive.

**Results**

**Validation of the EIA**

The EIA was first validated with urethral specimens from the 398 male patients in Group A. The test was compared with a standard cell culture method for *C. trachomatis*, as described above. Table 1 relates the results of the Pharmacia Chlamydia EIA with the cell culture test for the detection of *C. trachomatis* in male urethral specimens. There were 28 specimens which were positive in both the EIA and culture tests. Thus the EIA test showed a sensitivity of 100% (28/28) when compared with cell culture. There were 20 specimens which were EIA positive, culture negative, and this subgroup will be discussed below. The EIA specificity was 95% (350/370) compared with cell culture.

**EIA test on urine and urethral samples**

The urine and urethral specimens from the 356 patients in Group B were tested in the Pharmacia EIA. Table 2 relates the results of the EIA test for *C. trachomatis* in urine and urethral samples. The corresponding urine and urethral specimens were tested in the same EIA test batch, to minimize intra-assay variations. There were 29 urethral specimens which yielded a positive EIA result. Thus, the urine specimens were positive in 24% (7/29) of those patients who yielded a positive EIA result in the urethral swabs. The prevalence in this group was 8% (29/356). All EIA positive specimens were confirmed with the blocking antibody test from the manufacturer. There were nine urine specimens which were positive in the EIA test. Within this group of nine, seven patients yielded a corresponding positive EIA test result in their urethral swabs. The remaining two patients had a negative EIA from the urethral swab. The median time since last micturition for positive EIA (urethral swab or urine) was 2.5 hours while that for EIA negative specimens was 2 hours.

**Discussion**

The validation of the EIA kit showed that in a male population with a *C. trachomatis* infection prevalence of 7% (see table 1), the test sensitivity was compared with cell culture. The test specificity was 95%. All screen EIA positive specimens were confirmed positive in the EIA with a different antibody (rabbit) from that used in the screening test (mouse monoclonal). The case notes were reviewed for the 20 urethral specimens which were EIA positive and culture negative. Within this subgroup of twenty patients six had presented to the clinic as contacts of chlamydia, while another eight

---

Table 1: Relation between the Pharmacia Chlamydia confirmatory EIA and culture for the detection of *C. trachomatis* in 398 male urethral specimens (group A)

<table>
<thead>
<tr>
<th>Pharmacia EIA</th>
<th>Positive</th>
<th>Negative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Culture positive</td>
<td>28</td>
<td>0</td>
<td>28</td>
</tr>
<tr>
<td>Culture negative</td>
<td>20</td>
<td>350</td>
<td>370</td>
</tr>
<tr>
<td>Total</td>
<td>48*</td>
<td>350</td>
<td>398</td>
</tr>
</tbody>
</table>

*Confirmed with blocking antibody.

EIA sensitivity 100% (28/28), specificity 95% (350/370).

Prevalence of culture—7% (28/398), by EIA—12% (46/398)

---

Table 2: Relation between the urine and urethral specimens from 356 male patients (group B) for the detection of *C. trachomatis* in the pharmacia confirmatory EIA

<table>
<thead>
<tr>
<th>Urine Specimens</th>
<th>Positive</th>
<th>Negative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Culture positive</td>
<td>7</td>
<td>22</td>
<td>29*</td>
</tr>
<tr>
<td>Culture negative</td>
<td>20</td>
<td>325</td>
<td>345</td>
</tr>
<tr>
<td>Total</td>
<td>0*</td>
<td>347</td>
<td>356</td>
</tr>
</tbody>
</table>

*Confirmed with blocking antibody.

EIA sensitivity 24% (7/29), specificity 99% (325/327).

Prevalence 8% (29/356)
had symptoms consistent with urethritis. There were six other patients who had no urethral symptoms or objective evidence of urethral inflammation and were probably false positives. This would tend to indicate that the specificity of the EIA in urethral swabs was better than 95%.

Throughout the study there were no indications that the culturing of these specimens was suboptimal and all specimens were promptly placed in liquid nitrogen immediately after patient sampling. There was no detectable activity in the EIA with Staphylococcus aureus which may give rise to non-specific binding via the Fc portion of the detector antibody (data not shown). Previous reports have shown that it is not unusual for some specimens (from both male and female patients) to be EIA positive, but culture negative.7 8 This EIA kit was thus sufficiently sensitive and specific to be used for the detection of C trachomatis in urethral specimens.

In screening for difficulty need not be 100%, provided that the sensitivity is high and a confirmatory test is available to exclude the false positives obtained in the screening test. Thus a urine test with high sensitivity (> 95%) would provide a very useful screening test due to its convenience and patient acceptability. The EIA results in this study demonstrated a low yield (9/356, 2.5%) in urine specimens. Compared with testing the urethral swab the urine test specificity was 99% (325/327) and the sensitivity was 24% (7/29) (see table 2). In a limited number of urine specimens, polyethylene glycol (PEG, MW 6,000) (6%) was used as a precipitating agent for C trachomatis. It was thought that this may increase the urine test sensitivity in the EIA by precipitating the extracellular organisms (including infected cells) in the urine samples. However, the results showed that the use of PEG did not increase the urine sensitivity in the EIA (data not shown).

Our results compare with those of others in which urine samples tested in different EIA kits showed sensitivities of 42%3 when compared with male urethral swabs and 37%4 when compared with female cervical/urethral swabs. The prevalence in their study populations were 11%3 and 7%4 which is similar to that in our study population of male patients. (Locally, the STD clinic has a C trachomatis prevalence of 4% in the female population).

It may be argued that the period before collection of the urine sample for EIA test and last micturition was too short for efficient detection of the organism by the EIA. However, in our study population, there was no correlation between the EIA positive results and the period before last micturition. It may also be argued that collection of the urine specimen prior to urethral swab would have increased the urine test sensitivity. In this case, it is not clear whether or not urethral swab sensitivity would be adversely affected if urine was collected first. However, urine collected first would affect smears for gonorrhea and polymorph counts. Our clinical practice is to swab for gonorrhoea and chlamydia and make urethral smears before urine samples are collected and examined.

The use of urine instead of a urethral swab would have greater convenience and patient acceptability and thus provide a useful screening procedure in many health care settings. The earlier report by Paul and Cault2 suggested that a single urine sample could be used for multiple test comparisons as it does not involve the attendant problem of multiple sampling, which may decrease the amount of chlamydia organisms or antigen, especially with latter collected samples. However, their study did not propose urine as a replacement specimen for urethral swab. In order for urine specimens to replace male urethral swabs, the urine test sensitivity would need to be 95% positive, when compared with the urethral positive disease, the test specified in the same system. Our results and those of others3 5 9 showed that, for the laboratory diagnosis of C trachomatis infection, urine specimens cannot replace male urethral specimens. However, other laboratories have reported varying sensitivities using urine specimens.2 10 This may reflect differences in assay systems. The patients in our study population may be considered at higher risk of chlamydial infection (that is, they were STD clinic clients), and the use of urine specimens from those with a lower risk of infection would provide an even lower yield of positive tests.

The authors wish to thank Pharmacia Australia for their support of this project.